- Home
- NGNE vs RFI Comparison
NGNE vs RFI Comparison
Compare NGNE & RFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- RFI
- Stock Information
- Founded
- NGNE 2003
- RFI 1992
- Country
- NGNE United States
- RFI United States
- Employees
- NGNE N/A
- RFI N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- RFI Investment Managers
- Sector
- NGNE Health Care
- RFI Finance
- Exchange
- NGNE Nasdaq
- RFI Nasdaq
- Market Cap
- NGNE 325.3M
- RFI 323.2M
- IPO Year
- NGNE N/A
- RFI N/A
- Fundamental
- Price
- NGNE $18.48
- RFI $12.10
- Analyst Decision
- NGNE Strong Buy
- RFI
- Analyst Count
- NGNE 7
- RFI 0
- Target Price
- NGNE $41.86
- RFI N/A
- AVG Volume (30 Days)
- NGNE 110.1K
- RFI 69.8K
- Earning Date
- NGNE 08-11-2025
- RFI 01-01-0001
- Dividend Yield
- NGNE N/A
- RFI 8.25%
- EPS Growth
- NGNE N/A
- RFI N/A
- EPS
- NGNE N/A
- RFI N/A
- Revenue
- NGNE N/A
- RFI N/A
- Revenue This Year
- NGNE N/A
- RFI N/A
- Revenue Next Year
- NGNE N/A
- RFI N/A
- P/E Ratio
- NGNE N/A
- RFI N/A
- Revenue Growth
- NGNE N/A
- RFI N/A
- 52 Week Low
- NGNE $6.88
- RFI $9.62
- 52 Week High
- NGNE $74.49
- RFI $12.52
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- RFI 52.30
- Support Level
- NGNE $19.59
- RFI $11.89
- Resistance Level
- NGNE $20.46
- RFI $12.07
- Average True Range (ATR)
- NGNE 1.23
- RFI 0.09
- MACD
- NGNE -0.20
- RFI 0.01
- Stochastic Oscillator
- NGNE 13.37
- RFI 60.71
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.